Neoplasms, Unknown Primary
8
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Paclitaxel/Carboplatin With or Without Cetuximab in CUP